Aspira Women’s Health (NASDAQ:AWH) Coverage Initiated at StockNews.com

by · The Markets Daily

Analysts at StockNews.com started coverage on shares of Aspira Women’s Health (NASDAQ:AWH – Get Free Report) in a research note issued on Sunday. The brokerage set a “hold” rating on the stock.

Aspira Women’s Health Stock Performance

Shares of AWH opened at $0.64 on Friday. The company has a 50 day moving average price of $0.76 and a 200-day moving average price of $0.95. Aspira Women’s Health has a fifty-two week low of $0.59 and a fifty-two week high of $5.65. The stock has a market capitalization of $10.67 million, a PE ratio of -0.53 and a beta of 1.42.

Institutional Investors Weigh In On Aspira Women’s Health

A hedge fund recently bought a new stake in Aspira Women’s Health stock. Pine Valley Investments Ltd Liability Co purchased a new position in Aspira Women’s Health Inc. (NASDAQ:AWH – Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 31,200 shares of the company’s stock, valued at approximately $25,000. Pine Valley Investments Ltd Liability Co owned about 0.19% of Aspira Women’s Health at the end of the most recent quarter. 12.19% of the stock is currently owned by institutional investors.

About Aspira Women’s Health

(Get Free Report)

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.

Featured Stories